These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19640511)

  • 21. [Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study].
    Gutiérrez-Suela F
    Farm Hosp; 2008; 32(2):83-90. PubMed ID: 18783707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Course of Psychosis in Schizophrenia With Alcohol Use Disorder: A Post Hoc Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness in Schizophrenia Phase 1 Study.
    Pathak S; Jiang Y; DiPetrillo L; Todtenkopf MS; Liu Y; Correll CU
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32220153
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.
    Mullins CD; Obeidat NA; Cuffel BJ; Naradzay J; Loebel AD
    Schizophr Res; 2008 Jan; 98(1-3):8-15. PubMed ID: 17596914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.
    Gómez-Revuelta M; Pelayo-Terán JM; Juncal-Ruiz M; Vázquez-Bourgon J; Suárez-Pinilla P; Romero-Jiménez R; Setién Suero E; Ayesa-Arriola R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2020 Apr; 23(4):217-229. PubMed ID: 31974576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.
    Faries D; Ascher-Svanum H; Zhu B; Correll C; Kane J
    BMC Psychiatry; 2005 May; 5():26. PubMed ID: 15921508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost of antipsychotic polypharmacy in the treatment of schizophrenia.
    Zhu B; Ascher-Svanum H; Faries DE; Correll CU; Kane JM
    BMC Psychiatry; 2008 Apr; 8():19. PubMed ID: 18394168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.
    Stauffer V; Ascher-Svanum H; Liu L; Ball T; Conley R
    BMC Psychiatry; 2009 Mar; 9():13. PubMed ID: 19335905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Understanding the results of CATIE in the context of the field.
    Glick ID
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):40-7. PubMed ID: 16816799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia.
    Sampford JR; Sampson S; Li BG; Zhao S; Xia J; Furtado VA
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010832. PubMed ID: 27370402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
    Daumit GL; Goff DC; Meyer JM; Davis VG; Nasrallah HA; McEvoy JP; Rosenheck R; Davis SM; Hsiao JK; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Oct; 105(1-3):175-87. PubMed ID: 18775645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simulation model to estimate 10-year risk of coronary heart disease events in patients with schizophrenia spectrum disorders treated with second-generation antipsychotic drugs.
    Darbà J; Kaskens L; Aranda P; Arango C; Bobes J; Carmena R; Rejas J
    Ann Clin Psychiatry; 2013 Feb; 25(1):17-26. PubMed ID: 23376866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of phase 3 of the CATIE schizophrenia trial.
    Stroup TS; Lieberman JA; McEvoy JP; Davis SM; Swartz MS; Keefe RS; Miller AL; Rosenheck RA; Hsiao JK;
    Schizophr Res; 2009 Jan; 107(1):1-12. PubMed ID: 19027269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics.
    Maher AR; Theodore G
    J Manag Care Pharm; 2012 Jun; 18(5 Suppl B):S1-20. PubMed ID: 22784311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.
    Dossenbach M; Arango-Dávila C; Silva Ibarra H; Landa E; Aguilar J; Caro O; Leadbetter J; Assunção S
    J Clin Psychiatry; 2005 Aug; 66(8):1021-30. PubMed ID: 16086618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
    Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
    Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic findings from the CATIE trial and their relation to tolerability.
    Nasrallah HA
    CNS Spectr; 2006 Jul; 11(7 Suppl 7):32-9. PubMed ID: 16816798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The stable patient with schizophrenia--from antipsychotic effectiveness to adherence.
    Thomas P
    Eur Neuropsychopharmacol; 2007 Mar; 17 Suppl 2():S115-22. PubMed ID: 17336766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.